3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Sarcoma
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
7
Ovarian Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms, Male
1
Interventions
pembrolizumab
23
Gemcitabine
14
Carboplatin
10
Nivolumab
9
Cyclophosphamide
9
olaparib
8
Specimen Handling
8
Paclitaxel
8
Trastuzumab
7
Magnetic Resonance Spectroscopy
6
fludarabine
5
Standard of Care
5
Irinotecan
5
Ipilimumab
5
Docetaxel
5
Cisplatin
5
Capecitabine
5
Biopsy
5
sargramostim
4
pertuzumab
4
palbociclib
4
enzalutamide
4
durvalumab
4
atezolizumab
4
aldesleukin
4
Taxes
4
Oxaliplatin
4
Fluorouracil
4
Erlotinib Hydrochloride
4
Early Intervention, Educational
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Genetic Counseling
×
Genitourinary
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled